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ABSTRACT
Objectives: Ovarian cancer is a heterogeneous disease, where chronic inflammation plays a key role in carcinogen-
esis. In this study,  it is aimed to analyze the relationship with prognosis and chemotherapy response to clinicopathological 
variables in epithelial ovarian cancers such as proliferation of PD-1 +, CD8 +, CD4 +, CD3 + T-lymphocytes infiltrating the 
tumor and tumor stroma.
Matrial and methods: Seventy-six cases diagnosed with primary epithelial ovarian tumor from biopsy or surgical resec-
tion materials were included in the study. Immunreactivity of CD3, CD4, CD8, PD1 was evaluated immunohistochemically 
in lymphocytes in tumor infiltrating  lymphocytes and stromal lymphocytes.
Results: Seventeen (22.4%) of the cases were Type I, 59 (77.6%) of them were Type II ovarian carcinoma. PD-1 positivity was 
observed in stromal and intraepithelial lymphocytes in 22 (28.9%) of 76 cases.  In the presence of PD-1 + T-lymphocytes that 
infiltrate tumor and stroma, disease-free survival are shorter (p = 0.037). The presence of stromal CD4 + and CD8 + T-lym-
phocytes was more common in late stage patients (p = 0.012, p = 0.036; respectively).  The disease-free and overall survival 
rate was statistically significantly shorter in the presence of CD8 + T lymphocytes (p = 0.009, p = 0.003; respectively).  
Conclusions: CD3, CD4 and CD8 may contribute to PD-1 mediated tumor control. Anti PD-1 therapy may be an alternative 
to chemotherapy in PD-1 positive patients. Identifying patients who do not respond to chemotherapy through PD-1 expres-
sion prior to immunotherapy will help develop potential personalized immunotherapy.
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INTRODUCTION
Ovarian cancers are the second most common malig-
nancy among gynecological malignancies, causing the most 
frequent death due to nonspecific symptomatology and the 
absence of effective diagnostic methods that provide early 
detection [1, 2]. According to global statistical data, approxi-
mately 295,414 new ovarian cancers and 184,799 deaths 
were reported worldwide in 2018 [3]. 
The immune system; it is considered to have a key role 
in carcinogenesis, especially the suspension of tumor de-
velopment. The increased concentration of tumor infiltrat-
ing lymphocyte (TIL) is associated with good prognosis in 
various types of cancer [4]. Recent advances in immuno-
therapy, particularly immune checkpoint inhibitors (ICIs), 
have increased interest in the new treatment strategy and 
the immune status of the cancer microenvironment [5]. 
New treatment strategies are needed as current treatment 
methods are not sufficient to increase the survival rate of 
patients with ovarian cancer. Nowadays, there are many 
ongoing clinical studies on the effectiveness of ICIs in ovar-
ian cancer [6].
The use of ICIs for cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4), programmed cell death-1 (PD-1) recep-
tor/programmed death-ligand 1 (PD) receptors in many 
cancer patients, particularly malignant melanoma, lung 
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cancer, and bladder cancer has been shown to increase 
overall survival [7]. TIL’s; CD4 + and CD8 + T-cells, natural 
killer (NK) cells, natural killer T lymphocytes (NKT), dendritic 
cells, CD3 + T-lymphocytes and CD20 + B-lymphocytes are 
involved in the antitumor immune response. These cells 
directly participate in the presentation of tumor antigens 
and/or the attack of tumor cells [3].
PD-1, also known as CD279, is mainly expressed through 
activated immune cells such as regulatory T (Treg)-cells and 
NK-cells. Thus, it prevents excessive immune response and 
protects normal cells from immune attack [8, 9]. PD-1 has 
two ligands, PD-L1 and PD-L2. In order for PD-1 to inhibit 
T-lymphocyte functions, it must be combined with PD-
L1 and PD-L2 ligands. The ligand commonly found in tumor 
cells is PD-L1. PD-L1, expressed in the micro-environment 
of the tumor, suppresses the immune response developing 
against the tumor [10]. PD-L1 is thought to play a role in the 
immunological escape mechanism that causes tumor cell 
growth, proliferation and metastasis [2]. Cancer immuno-
therapy is due to the emergence of T-cells through immune 
checkpoint blockage and its functional role to eliminate 
tumor cells [8]. The expression of immune checkpoint mol-
ecules carries prognostic and predictive instructions.
 In this study,  it is aimed to analyze the relationship with 
prognosis and chemotherapy response to clinicopathologi-
cal variables in epithelial ovarian cancers such as prolifera-
tion of PD-1 +, CD8 +, CD4 +, CD3 + T-lymphocytes infiltrat-
ing the tumor and tumor stroma, tumor type, tumor size, 
lymphovascular invasion, lymph node invasion, tumor stage.
MATERIAL AND METHODS
Patients
Seventy-six cases diagnosed with epithelial ovarian tu-
mor from biopsy or surgical resection materials at Pamuk-
kale University Faculty of Medicine, Department of Pathol-
ogy, between 2011 and 2019 were included in the study. 
The cases were retrospectively reviewed.
The ethics approval of this study was accepted by the 
Non-Interventional Clinical Research Ethics Committee of 
Pamukkale University at the meeting dated 19.11.2019 and 
numbered 60116787-020/83868.
Epithelial ovarian tumors has been reclassified as 
type I and II tumors according to the new carcinogenesis 
model. Type I tumors originate from extra-ovarian lesions 
that can turn into malignant lesions; 1. clear cell carcinoma, 
seromucinous carcinoma, endometrioid carcinoma known 
to be associated with endometriosis 2. low grade serous 
carcinomas; 3. mucinous carcinoma and malignant bren-
ner tumors. Type II tumors developed from intraepithelial 
lesions in the fallopian tube and divided into three groups: 
1. high grade serous carcinoma, 2. carcinosarcoma, and 
3. undifferentiated carcinoma (Fig. 1) [11]. The stage of the 
tumor was determined according to the International Fed-
eration of Gynecology and Obstetrics (FIGO) criteria [12]. 
While primary epithelial ovarian tumors were included in 
the study; secondary malignant neoplasms (metastases) 
and primary nonepithelial ovarian tumors were excluded. 
Patient information such as age, stage, and treatment in-
formation of the cases were obtained from the gynecology 
Figure 1. Expanded dualistic model of ovarian carcinogenesis. Ovarian carcinomas derive from endometrial tissue, fallopian tube tissue, germ cells, 
and transitional epithelium. Type I carcinomas comprise endometrioid, clear cell, LG serous, and mucinous carcinomas. Seromucinous carcinomas 
and malignant Brenner tumors are rare. It was recently proposed that seromucinous neoplasms be designated mixed Müllerian tumors. Type II 
carcinomas are largely composed of HG serous carcinoma, carcinosarcoma, and undifferentiated carcinoma. Transitional cell indicates metaplastic 
transitional epithelium at the tuboperitoneal junction; HG — high-grade; LG — low-grade; SET — solid pseudoendometrioid transitional [11]
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department, data such as disease-free survival and overall 
survival were obtained from the patient files of the depart-
ment of oncology.
While TAH + BSO + lymph node dissection was applied 
to 69 (90.8%) of the cases, 7 (9.2%) were performed biopsy. 
The mean age of the cases is 55 (24–81). Considered as 
older than 55, younger under 55. The mean tumor diam-
eter is 0.9 cm (0.5–11.5). 42 (55.3%) of them are located 
bilaterally. 17 (22.4%) of the cases were Type I, 59 (77.6%) 
of them were Type II ovarian carcinoma. Their distribution 
is 59 (77.6%) high grade serous carcinoma, 8 (10.5%) bor-
derline serous carcinoma, 4 (5.3%) clear cell carcinoma, 
3 (3.9%) endometrioid carcinoma, 2 (2.6%) is in the form 
of mucinous carcinoma. In immunohistochemical analysis 
for ER 48/59 (82.7%), PR 33/52 (63.4%), C-erb 2 1/6 (16.6%), 
PAX8 14/15 (93.3%), WT1 39/71 (54.9%), p53 40/46 (86.9%), 
CEA 125 38/39 (97.4%) were positive in cases. Capsule inva-
sion was present in 36 (47.4%) of the cases and lymphovas-
cular invasion in 12 (15.8%). 23 (30.3%) of the intraabdomi-
nal fluid is malignant. 28 (36.8%) of the cases are early stage 
(I–II), 36 (47.4%) of the cases are late stage (III–IV). Recurrence 
was observed in 27 (35.5%) of the cases, and the disease-free 
survival was 29.6 ± 28.7 months. 67 (88.7%) of the cases 
died and the overall survival time was 34.8 ± 30.8 months.
Immunohistochemistry (IHC)
A tumor-rich paraffin block was selected for immuno-
histochemical examination. Ventana Benchmark XT™ fully 
automated staining device was used with the procedure 
suitable for sections of about 3–5 microns thick taken on 
lysine slide from selected paraffin blocks. CD3 (Dako, pre-
diluted, ready-to-use antibody antibody; Rabbit Polyclonal 
Primary Antibody), CD4 (Dako, prediluted- auto-ready an-
tibody; Mouse Monoclonal Primary Antibody, clone 4B12), 
CD8 (Dako, prediluted- auto-ready antibody; Mouse Mon-
oclonal Primary Antibody, clone C8/144B), PD-1 (CD279) 
(Cell Marque, predilute-auto ready-to-use antibody; mouse 
monoclonal, clone: NAT105) antibodies were used for im-
munohistochemical staining. The ultraView Universal DAB 
detection kit is used for all staining. The primary antibody 
stage was omitted for negative control in immunohisto-
chemical staining. For positive control, tonsil tissue for CD3, 
CD8, CD4 and placental chorionic villus for PD-1 were used. 
The slides examined were evaluated by two pathologists 
(FB, YAK) for the immunoreactivity of CD3, CD4, CD8, PD1, 
taking into account cytoplasmic and/or membranous stain-
ing in tumor infiltrating  lymphocytes and stromal lympho-
cytes. Percentage ratio for CD3, CD4, CD8 T lymphocytes 
in lymphocytes infiltrating the tumor and stroma is given. 
Median value was taken as cutt-off. Above the median value 
was classified as high, below the median value was classi-
fied as low.  For PD-1, it was evaluated as < 1% negative 
and ≥ 1% positive.
Statistical evaluation
Descriptive values of quantitative continuous variables 
(such as age) were examined using standard descriptive 
statistical methods (arithmetic mean, standard deviation, 
median, etc.). Categorical variables (asset frequencies) are 
given together with their frequencies and percentages in 
the total. Comparisons of categorical variables were made 
by Chi-square or Fischer’s Exact Test, depending on the state 
of the case distributions. Kaplan Mayer test was performed 
for disease-free survival and overall survival.
RESULTS
PD-1 positivity was observed in stromal and intratu-
moral lymphocytes in 22 (28.9%) of 76 cases (Fig. 2A,  B). 
PD-1 positivity in intratumoral lymphocytes was found 
to be higher in elderly patients than in younger patients 
(p = 0.030). Distribution of PD-1 positive cases by tumor 
types; 18/59 (30.5%) of our high-grade serous carcinoma 
cases, in 1/2 (50%) of mucinous carcinoma, 2/8 (25%) of 
borderline serous carcinoma, 1/4 (25%) of our clear cell carci-
noma cases showed positive PD-1, in addition no PD-1 posi-
tivity was found in a patient with endometrioid carcinoma. 
18/22 (81%) of PD-1 positive T-lymphocytes were seen in 
patients with type II ovarian carcinoma, 4/22 (19%) were 
seen in patients with type I ovarian carcinoma, this relation-
ship was not statistically significant (p = 0.500). In PD-1 posi-
tive group, 17 (77.3%) of 22 cases were exitus (p = 0.029), 
and recurrence was detected in 6 (27.3%) (p = 0.337). In the 
presence of PD-1 + T-lymphocytes that infiltrate tumor and 
stroma, disease-free survival and overall survival are shorter 
than PD-1 negative cases (p = 0.037, p = 0.063; respectively). 
The relationship between the proliferation of stromal PD-1, 
CD8, CD4, CD3 T lymphocytes and clinicopathological vari-
ables is shown in Table 1.
High incidence of stromal CD3 + T-lymphocytes in ear-
ly-stage ovarian carcinomas is associated with longer dis-
ease-free survival (p = 0.087). Also, high incidence of stromal 
CD3 + T-lymphocytes in Type I ovarian carcinomas is associ-
ated with longer disease-free survival (p = 0.066) (Fig. 2C, D). 
The presence of stromal CD3 + T-lymphocyte was found to 
be higher in living patients than in ex patients (p = 0.093). 
Stromal CD3+ T-lymphocytes was higher in PD-1 positive 
patients than PD-1 negative patients (p = 0.012) (Tab. 2). 
In the survival statistics, in the presence of PD-1 positive 
CD3 + T-lymphocyte, disease-free survival (p = 0.032), overall 
survival (p = 0.063) tends to be longer. 
The disease-free and overall survival rate was statistically 
significantly shorter in the presence of CD8 + T-lymphocytes 
347
Yeliz Arman Karakaya et al., CD3, CD4, CD8, PD-1 in ovarian cancers
www. journals.viamedica.pl/ginekologia_polska
(p = 0.009, p = 0.003; respectively). In patients receiving 
chemotherapy, the disease-free and overall survival rate was 
shorter in the presence of CD8 + T-lymphocytes (p = 0.569, 
p = 0.014; respectively).
The presence of stromal CD4 + T-lymphocyte above the 
median value was more common in type II ovarian carci-
nomas than in type I (p = 0.080) (Tab. 3). The presence of 
stromal CD4 + and CD8 + T lymphocytes was more common 
in late stage patients than in the early stage (p = 0.012, 
p = 0.036; respectively) (Fig. 3A–D). There was no statis-
tically significant relationship between disease-free sur-
vival and overall survival in the presence of PD-1 posi-
tive CD4 + T-lymphocyte in survival statistics (p = 0.789, 
p = 0.863).
There was no statistically significant relationship be-
tween the proliferation of intratumoral PD-1, CD8, CD4, 
CD3 T-lymphocytes and clinicopathological variables.
There was no statistically significant relationship be-
tween ER, PR, C-erb 2, PAX8, WT1, p53, CEA 125 immuno-ex-
pression and CD3, CD4, CD8 and PD-1 expression.
Figure 2A. Serous ovarian carcinoma, H-E, ×200; B. Stromal PD-1 + lymphocytes, IHK, ×200; C, D. High incidence of stromal CD3 + T-lymphocytes 
(C — H-E, ×200, D — CD 3 IHK, ×200) 
Figure 3A, B. The presence of stromal CD4 + T-lymphocyte was common in type II ovarian carcinomas (A — H-E, × 200, B. CD 4 IHK, ×200); C, D. 
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Table 1. Relationship between proliferation of stromal PD-1, CD8, CD4, CD3 T-lymphocytes and clinicopathological variables
Stromal CD3L CD3H CD4L CD4H CD8L CD8H PD-1L PD-1H
n/%
Tumor diameter (n = 58) 
> 0.5 cm (n = 38) 8 (13.8) 30 (51.7) 20 (34.5) 18 (31.0) 19 (32.8) 19 (32.8) 26 (44.8) 12 (20.7)
< 0.5 cm (n = 20) 8 (13.8) 12 (20.7) 7 (12.1) 13 (22.4) 5 (8.6) 15 (25.8) 17 (29.3) 3 (5.2)
Histological  grade (n = 76)
Low (n = 17) 6 (7.9) 11 (14.5) 11 (14.5) 6 (7.9) 10 (13.2) 7 (9.2) 13 (17.1) 4 (5.3)
High (n = 59) 12 (15.8) 47 (61.8) 24 (31.6) 35 (46.0) 19 (25.0) 40 (52.6) 41 (53.9) 18 (23.7)
Stage (n = 64)
I/II (n = 28) 8 (12.5) 20 (31.3) 19 (29.7) 9 (14.1) 15 (23.5) 13 (20.3) 20 (31.2) 8 (12.5)
III/IV (n = 36) 10 (15.6) 26 (40.6) 13 (20.3) 23 (35.9) 10 (15.6) 26 (40.6) 27 (42.2) 9 (14.1)
Lymphovascular invasion (n = 25)
Yes (n = 12) 3 (12.0) 9 (36.0) 3 (12.0) 9 (36.0) 4 (16.0) 8 (32.0) 9 (36.0) 3 (12.0)
No  (n = 13) 4 (16.0) 9 (36.0) 7 (28.0) 6 (24.0) 8 (32.0) 5 (20.0) 8 (32.0) 5 (20.0)
Capsule  invasion (n = 51)
Yes (n = 36) 9 (17.7) 27 (52.9) 15 (29.4) 21 (41.2) 16 (31.4) 20 (39.2) 28 (54.9) 8 (15.7)
No (n = 15) 6 (11.7) 9 (17.7) 8 (15.7) 7 (13.7) 6 (11.7) 9 (17.7) 11 (21.6) 4 (7.8)
Metastasis  (n = 72)
Yes (n = 45) 12 (16.7) 33 (45.8) 15 (20.8) 30 (41.7) 12 (16.7) 33 (45.8) 34 (47.2) 11 (15.3)
No (n = 27) 6 (8.3) 21 (29.2) 19 (26.4) 8 (11.1) 14 (19.4) 13 (18.1) 18 (25.0) 9 (12.5)
Intraabdominal  fluid (n = 33)
Benign (n = 10) 0 (0.0) 10 (30.3) 3 (9.1) 7 (21.2) 2 (6.1) 8 (24.2) 4 (12.1) 6 (18.2)
Malign (n = 23) 5 (15.2) 18 (54.5) 10 (30.3) 13 (39.4) 11 (33.3) 12 (36.4) 15 (45.5) 8 (24.2)
Nuks (n = 76)
Yes (n = 27) 7 (9.2) 20 (26.3) 13 (17.1) 14 (18.4) 6 (7.9) 21 (27.6) 21 (27.6) 6 (7.9)
No (n = 49) 11 (14.5) 38 (50.0) 22 (29.0) 27 (35.5) 23 (30.3) 26 (34.2) 33 (43.4) 16 (21.1)
Ex (n = 75)
Yes (n = 67) 18 (24.0) 49 (65.3) 32 (42.7) 35 (46.6) 26 (34.7) 41 (54.6) 50 (66.7) 17 (22.7)
No (n = 8) 0 (0.0) 8 (10.7) 3 (4.0) 5 (6.7) 3 (4.0) 5 (6.7) 3 (4.0) 5 (6.6)
Table 2. Intratumoral and stromal CD3, CD4, CD8 ratios in PD-1 positive and negative cases
Low High p
CD3 intratumoral 
PD-1 negative 20/54 37% 34/54 63% 
0.416
PD-1 positive 8/22 36% 14/22 64%
CD4 intratumoral 
PD-1 negative 12/54 22% 42/54 78% 
0.695
PD-1 positive 4/22 18% 18/22 82%
CD8 intratumoral 
PD-1 negative 27/54 50% 27/54 50% 
0.279
PD-1 positive 8/22 36% 14/22 64%
CD3 stromal 
PD-1 negative 17/54 31% 25/54 47% 
0.012
PD-1 positive 10/ 22 45% 12/22 55%
CD4 stromal 
PD-1 negative 29/54 53% 25/54 47% 
0.947
PD-1 positive 10/ 22 45% 12/22 55%
CD8 stromal 
PD-1 negative 27/54 50% 27/54 50% 
0.468
PD-1 positive 8/22 36% 14/22 64%
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 DISCUSSION
The presence of TILs in the intratumoral and stromal 
component of epithelial tumors of the ovary is an important 
prognostic factor. The diversity of stromal TILs with tumor 
cell proliferation, invasion, and matrix rearrangement that 
causes carcinogenesis resulting in different survival creates 
a tumor-specific microenvironment [13]. Tumor cells modify 
the tumor microenvironment, both to suppress T-cells and 
to stimulate tumorigenic inflammation [14]. Afterwards, 
PD1 becomes apparent in this process and limits T-cell ac-
tivity in the tumor microenvironment [15]. In the study of 
Webb et al., PD-1 was positive in 22.1% of 489 ovarian can-
cers. PD-1 positivity was seen in 75 (38.5%) of 195 high-grade 
serous carcinomas, 22 (17.6%) of 125 endometrioid carci-
nomas, 11 (8.6%) of 128 clear cell carcinomas in this study, 
while 30 mucinous and 11 low-grade serous tumor was 
PD-1 negative [16]. In our study, PD-1 positivity was ob-
served in 22 (28.9%) of 76 cases. PD-1 positivity was seen 
in 18 (30.5%) of 59 high-grade serous carcinomas, 1 (50%) 
of 2 mucinous carcinomas, 2 (25%) of 8 borderline serous 
carcinomas, 1 (25%) of 4 clear cell carcinomas, was not seen 
in endometrioid carcinoma in the current study.
Infiltration of PD-1 + lymphocytes is associated with 
distant metastasis, recurrence and poor prognosis in most 
tumor types [2, 17]. Wieser et al. found poor prognosis in 
PD-1 positivity at 170 cases of ovarian cancer series [18]. 
Similarly, in our study, the disease-free survival and overall 
survival duration were shorter at infiltration of stromal and 
intraepithelial PD-1 + lymphocytes.
Transformed tumor cells as a source of tumor-associated 
antigen or neoantigen may induce an immune response. 
After all, cytotoxic T-cells contribute to the elimination of tu-
mor cells [19]. Zhang et al. (2003) reported that CD3 + T-lym-
phocytes show more expression in the advanced stages of 
serous ovarian carcinomas [20, 21]. In a recent study, higher 
intraepithelial CD3 and CD8 TIL scores were significantly as-
sociated with longer survival in univariate and multivariate 
analyzes [22]. In another study, no correlation was found in 
survival analysis with stromal TILs in ovarian cancer. Accord-
ingly, the importance of evaluating TILs for each tumor type 
is emphasized [23]. In our study, high prevalence of stromal 
CD3 positive lymphocytes in Type I ovarian carcinomas 
and early stage patients was associated with good prog-
nosis. Stromal CD3 positivity was higher in living patients 
than ex patients. CD3 positivity was higher in PD-1 positive 
group and was associated with good prognosis. Sato et al. 
[23] stated that the presence of CD8 + T-lymphocytes in 
ovarian tumors is associated with good prognosis. They 
reported that high expression of CD8 + T-lymphocytes in 
the tumor was observed, but not in the tumor stroma [23]. 
In another study, CD8 + T-lymphocyte infiltration was found 
to be associated with advanced stage, high tumor grade, 
and metastasis in the epithelial tumors of the ovary [24, 
25], and therefore it was advocated to adversely affect the 
antitumor immune response [26]. According to the litera-
ture, there is a disagreement over the role of CD8 in the 
prognosis of ovarian cancer. In our study, the presence of 
stromal CD8 + TIL was more common in late stage patients 
than in the early stage. The presence of CD8 + T-lymphocytes 
has been associated with a worse prognosis.
Hamanishi et al. [27], showed high rates of CD4 + TILs 
in cases of ovarian cancer with better prognosis. These cells 
Table 3. Intratumoral and stromal PD-1, CD3, CD4, CD8 ratios in Type 1 and Type 2 ovarian carcinomas
Type I Ovarian 
Carcinoma
n = 17 (22.4%)
Type II Ovarian 
Carcinoma
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can recognize cancer antigens and mature to type-1 helper 
cells (Th1). Although the mechanism is uncertain, it can ac-
tivate M1 macrophages through interleukin-12 or interferon 
gamma secretion [27]. In studies conducted in different 
years, the presence of intraepithelial CD4 + T-lymphocytes 
has been associated with better survival [6, 28–30]. In our 
study, the presence of stromal CD4 + T-lymphocyte was 
more common in late stage patients than in the early stage. 
The presence of stromal CD4 T-lymphocyte was more preva-
lent in type II ovarian carcinomas than in type I. However, 
no significant relationship was found with the prognosis.
Cancer immunotherapy has been a controversial issue 
for years, but studies in this area reached a milestone in 
2014. Antibodies specifically blocking PD-1 became avail-
able for melanoma in 2014 and went into use for non-small 
cell lung cancer (NSCLC) in the United States, the Euro-
pean Union and Japan, in 2015, primarily approved by the 
Food and Drug Administration (FDA) [31]. The FDA approved 
the use of anti-PD-1 antibody pembrolizumab for solid can-
cers with microsatellite instability (MSI)-H or mismatch repair 
(MMR) deficiency in May 2017 [6]. Currently, two classes of 
FDA-approved immunotherapy for clinical use are PD-1 / PD-
L1 and CTLA-4 inhibitors [32]. New agents targeting other 
courses of the immune system are in the research phase [33]. 
Until now, single-agent PD-1 blockade has shown moderate 
activity in patients with ovarian carcinoma, with 15% and 
8% response rates reported in nivolumab and pembroli-
zumab studies, respectively [19]. Phase II clinical study in 
ovarian cancer has shown that nivolumab, a PD-1 receptor 
blocker, is well tolerated and offers a 45% disease control 
rate [34]. A recent update to a patient cohort demonstrated 
the ongoing clinical benefit even after drug discontinua-
tion. In addition, Pembrolizumab, a PD-1 blocker similar to 
Nivolumab, currently shows good tolerance and promising 
disease control on patients with ovarian cancer in early 
results. Therefore, it is important to identify biomarkers for 
immune checkpoint inhibitors in ovarian cancers. There 
are about 100 clinical trials testing PD-1 blockers, many of 
which focus on ovarian cancer [35]. PD-1 inhibition ensures 
proliferation of circulating tumor-specific CD8 + T-cells and 
reduces the functional depletion of specific T-cells [11]. 
To improve our current knowledge about the immuno-
logical environment of epithelial ovarian tumors, spesific 
immune cells need to be further investigated in different 
region tumors [3].
CONCLUSIONS
In our study, three important results were obtained. 
Firstly, PD-1 is positive in 28.9% of stromal and intraepithelial 
lymphocytes in our cases. CD3 positivity was higher in stro-
mal and intraepithelial T-lymphocytes of these cases, which 
is associated with good prognosis. Second, infiltration of 
intraepithelial and stromal PD-1 + T-lymphocytes has been 
associated with poor prognosis. Third, stromal CD 4+ and CD 
8+ T-lymphocytes are more common in late stages. In addi-
tion, the presence of CD 3 + T-lymphocytes is associated with 
good prognosis, while the presence of CD8 + T-lymphocytes 
is associated with poor prognosis. As a result, we think that 
CD3, CD4 and CD8 may contribute to PD-1 mediated tumor 
control. Anti PD-1 therapy may be an alternative to chemo-
therapy in PD-1 positive patients. Identifying patients who 
do not respond to chemotherapy through PD-1 expres-
sion prior to immunotherapy will help develop potential 
personalized immunotherapy and will help patients avoid 
unnecessary treatment.
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